JOHNSON & JOHNSONJNJ

JOHNSON & JOHNSON Segments Disclosure

10-KFiled Feb 11, 202610 min read
Segments of business and geographic areas
Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
INNOVATIVE MEDICINE
Oncology
U.S.$13,65910,8548,46225.8 %28.3 
International11,7219,9269,19918.1 7.9 
Worldwide25,38020,78117,66122.1 17.7 
CARVYKTI
U.S.1,49286946971.6 85.2 
International3959430**
Worldwide1,88796350095.9 92.7 
DARZALEX
U.S.8,2666,5885,27725.5 24.8 
International6,0855,0824,46719.7 13.8 
Worldwide14,35111,6709,74423.0 19.8 
ERLEADA
U.S.1,4531,2821,06513.4 20.3 
International2,1211,7171,32223.5 29.8 
Worldwide3,5742,9992,38719.2 25.6 
IMBRUVICA
U.S.8921,0201,051(12.5)(3.0)
International1,9312,0182,214(4.3)(8.8)
Worldwide2,8233,0383,264(7.1)(6.9)
RYBREVANT/ LAZCLUZE(1)
U.S.53425766**
International2007027**
Worldwide73432793**
TALVEY(2)
U.S.3402415640.9 *
International123467**
Worldwide4632876361.3 *
TECVAYLI
U.S.4444183346.3 25.3 
International2261316172.8 *
Worldwide67054939522.1 38.8 
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
ZYTIGA /abiraterone acetate
U.S.233450(33.2)(32.2)
International480597837(19.7)(28.6)
Worldwide502631887(20.4)(28.8)
OTHER ONCOLOGY
U.S.2141459347.5 55.9 
International162172235(6.0)(26.8)
Worldwide37631732818.5 (3.4)
Immunology
U.S.9,87211,35511,539(13.1)(1.6)
International5,8566,4736,513(9.5)(0.6)
Worldwide15,72817,82818,052(11.8)(1.2)
REMICADE
U.S.1,1711,0091,14316.0 (11.7)
U.S. Exports7498147(24.8)(33.0)
International5234975495.3 (9.5)
Worldwide1,7681,6051,83910.2 (12.8)
SIMPONI / SIMPONI ARIA
U.S.1,1931,0821,12410.3 (3.8)
International1,4751,1081,07333.1 3.3 
Worldwide2,6682,1902,19721.8 (0.3)
STELARA
U.S.3,8476,7206,966(42.7)(3.5)
International2,2303,6413,892(38.7)(6.4)
Worldwide6,07810,36110,858(41.3)(4.6)
TREMFYA
U.S.3,5292,4432,14744.5 13.7 
International1,6261,22799932.5 22.8 
Worldwide5,1553,6703,14740.5 16.6 
OTHER IMMUNOLOGY
U.S.59311*(74.1)
International200*—
Worldwide61311*(74.1)
Neuroscience
U.S.5,1514,3984,06517.1 8.2 
International2,6862,7183,076(1.2)(11.6)
Worldwide7,8377,1157,14010.1 (0.4)
CAPLYTA(3)
U.S.700——*—
International———— —
Worldwide700——*—
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
CONCERTA / methylphenidate
U.S.82134230(38.6)(41.7)
International502507554(1.2)(8.4)
Worldwide584641783(9.0)(18.1)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.2,7253,1252,897(12.8)7.9 
International1,0851,0971,218(1.1)(9.9)
Worldwide3,8104,2224,115(9.8)2.6 
SPRAVATO
U.S.1,48592958959.9 57.8 
International21014810041.9 48.2 
Worldwide1,6961,07768957.4 56.4 
OTHER NEUROSCIENCE
U.S.159210349(24.5)(39.8)
International8899651,204(7.9)(19.8)
Worldwide1,0481,1751,553(10.9)(24.3)
Pulmonary Hypertension
U.S.3,2233,1432,6972.6 16.5 
International1,2141,1401,1176.5 2.0 
Worldwide4,4374,2823,8153.6 12.3 
OPSUMIT/OPSYNVI(4)
U.S.1,6331,5571,2924.8 20.5 
International6926686813.7 (1.9)
Worldwide2,3252,2251,9734.5 12.8 
UPTRAVI
U.S.1,5361,5111,3261.7 13.9 
International36630725519.4 20.1 
Worldwide1,9021,8171,5824.7 14.9 
OTHER PULMONARY HYPERTENSION
U.S.547579(27.0)(5.1)
International155165182(6.2)(9.3)
Worldwide209240260(12.7)(7.7)
Infectious Diseases
U.S.1,2641,3541,500(6.6)(9.8)
International1,9772,0422,918(3.2)(30.0)
Worldwide3,2413,3964,418(4.6)(23.1)
EDURANT / rilpivirine
U.S.263135(18.4)(10.0)
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
International1,4611,2411,11517.7 11.2 
Worldwide1,4861,2721,15016.9 10.6 
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
U.S.1,2261,3111,446(6.5)(9.4)
International353401408(11.9)(1.7)
Worldwide1,5791,7121,854(7.7)(7.7)
OTHER INFECTIOUS DISEASES(5)
U.S.1211196.6 (41.0)
International1634011,395(59.3)*
Worldwide1754121,414(57.5)*
Cardiovascular / Metabolism / Other
U.S.3,1752,8662,90610.8 (1.4)
International603696765(13.3)(9.1)
Worldwide3,7783,5623,6716.1 (3.0)
XARELTO
U.S.2,6332,3732,36511.0 0.3 
International———— — 
Worldwide2,6332,3732,36511.0 0.3 
OTHER
U.S.5424945419.8 (8.8)
International603696765(13.3)(9.1)
Worldwide1,1451,1891,306(3.7)(8.9)
TOTAL INNOVATIVE MEDICINE
U.S.36,34433,97031,1697.0 9.0 
International24,05722,99423,5904.6 (2.5)
Worldwide60,40156,96454,7596.0 4.0 
MEDTECH
Cardiovascular
U.S.5,3054,5133,63317.5 24.2 
International3,6233,1942,71713.4 17.6 
Worldwide8,9287,7076,35015.8 21.4 
ELECTROPHYSIOLOGY
U.S.2,8912,7382,4585.6 11.4 
International2,7432,5292,2308.5 13.4 
Worldwide5,6345,2674,6887.0 12.3 
ABIOMED
U.S.1,3931,2131,06614.9 13.7 
International35828424026.4 18.2 
Worldwide1,7511,4961,30617.1 14.5 
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
SHOCKWAVE(6)
U.S.897442—**
International249122—**
Worldwide1,146564—**
OTHER CARDIOVASCULAR
U.S.1241201093.1 10.7 
International2732602474.9 5.3 
Worldwide3973803564.3 6.9 
Orthopaedics
U.S.5,7205,6895,5250.5 3.0 
International3,5383,4703,4172.0 1.5 
Worldwide9,2589,1588,9421.1 2.4 
HIPS
U.S.1,0801,0579962.1 6.2 
International5945815642.2 3.0 
Worldwide1,6741,6381,5602.1 5.0 
KNEES
U.S.9249228960.2 2.9 
International6636235596.5 11.3 
Worldwide1,5871,5451,4562.7 6.1 
TRAUMA
U.S.2,0582,0131,9492.2 3.3 
International1,0881,0361,0305.0 0.6 
Worldwide3,1463,0492,9793.2 2.3 
SPINE, SPORTS & OTHER
U.S.1,6581,6961,684(2.2)0.7 
International1,1931,2301,263(3.0)(2.6)
Worldwide2,8522,9262,947(2.5)(0.7)
Surgery
U.S.4,1574,0034,0313.9 (0.7)
International5,9805,8426,0062.4 (2.7)
Worldwide10,1379,84510,0373.0 (1.9)
ADVANCED
U.S.1,9001,8381,8333.4 0.2 
International2,6782,6502,8371.0 (6.6)
Worldwide4,5774,4884,6712.0 (3.9)
GENERAL
U.S.2,2582,1652,1984.3 (1.5)
International3,3023,1923,1683.4 0.8 
Worldwide5,5605,3585,3663.8 (0.2)
 Sales to Customers % Change
(Dollars in Millions)202520242023’25 vs. ’24’24 vs. ’23
Vision
U.S.2,2252,1282,0864.6 2.0 
International3,2433,0182,9867.4 1.1 
Worldwide5,4685,1465,0726.3 1.5 
CONTACT LENSES / OTHER
U.S.1,7541,6841,6264.1 3.6 
International2,1572,0492,0765.3 (1.3)
Worldwide3,9103,7333,7024.8 0.8 
SURGICAL
U.S.4714444606.1 (3.4)
International1,08696991012.1 6.5 
Worldwide1,5581,4131,37010.2 3.2 
TOTAL MEDTECH   
U.S.17,40816,33215,2756.6 6.9 
International16,38415,52515,1255.5 2.6 
Worldwide33,79231,85730,4006.1 4.8 
WORLDWIDE   
U.S.53,75250,30246,4446.9 8.3 
International40,44138,51938,7155.0 (0.5)
Worldwide$94,19388,82185,1596.0 %4.3 
*    percentage greater than 100% or not meaningful
(1)Previously in Other Oncology, Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2)Previously in Other Oncology
(3)Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025
(4)In 2024 OPSYNVI was in Other Pulmonary Hypertension
(5)Includes the Covid-19 Vaccine in 2024 and 2023
(6)Acquired on May 31, 2024
Income Before Tax by Segment
(Dollars in Millions)
2025 (3)
2024 (4)
2023 (5)
Innovative
Medicine		MedTechTotalInnovative
Medicine		MedTechTotalInnovative
Medicine		MedTechTotal
Sales to customers$60,40133,79256,96431,85754,75930,400
Cost of products sold15,64614,54914,03613,34513,71512,722
Selling, marketing and administrative 11,37511,35410,90610,8129,84210,476
Research and development expense11,8272,83813,5293,70311,9633,122
Other segment items(1)
(713)938(426)257993(589)
Segment income before tax$22,2664,11326,37918,9193,74022,65918,2464,66922,915
(Income) Expense not allocated to segments(2)
(6,202)5,9727,853
Worldwide total$32,58116,68715,062
 Identifiable Assets
(Dollars in Millions)20252024
Innovative Medicine$78,05757,070
MedTech86,48284,322
Total164,539141,392
General corporate(6)
34,67138,712
Worldwide total$199,210180,104
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)202520242023202520242023
Innovative Medicine$2,0761,7101,653$3,7723,7603,847
MedTech2,5012,4432,3723,4903,2372,943
Segments total4,5774,1534,0257,2626,9976,790
Discontinued operations——162——383
General corporate255271356241342313
Worldwide total$4,8324,4244,543$7,5037,3397,486
 Sales to Customers
Long-Lived Assets (7)
(Dollars in Millions)20252024202320252024
United States$53,75250,30246,444$89,39270,670
Europe21,53520,21220,41027,98727,267
Western Hemisphere excluding U.S. 4,8754,7144,5492,2041,728
Asia-Pacific, Africa14,03113,59313,7561,5441,454
Segments total94,19388,82185,159121,127101,119
General corporate1,2171,217
Other non long-lived assets76,86677,768
Worldwide total$94,19388,82185,159$199,210180,104
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues. In fiscal year 2024, the Company had three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1%, and 14.2% of the total gross revenues.
(1)Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(2)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal year 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion.
(3)Innovative Medicine segment income before tax includes:
• Acquisition, integration and divestiture related net expense of $0.4 billion primarily related to the Intra-Cellular and Halda acquisitions
MedTech segment income before tax includes:
•Litigation expense of $0.9 billion primarily related to the Auris shareholder litigation
•Acquisition, integration and divestiture related net income of $0.2 billion, primarily driven by a contingent value right liability reduction associated with Abiomed
•A restructuring related charge of $0.5 billion
•A gain on the sale of securities of $0.2 billion
(4)Innovative Medicine segment income before tax includes:
•Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)
•Monetization of royalty rights of $0.3 billion
•Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia
•An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
•A restructuring related charge of $0.1 billion
•One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion
•Favorable changes in the fair value of securities of $0.1 billion
MedTech segment income before tax includes:
•Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave
•Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition
•A gain of $0.2 billion related to the Acclarent divestiture
•A Medical Device Regulation charge of $0.2 billion
•A restructuring related charge of $0.2 billion
(5)Innovative Medicine segment income before tax includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion
•A restructuring related charge of $0.5 billion
•Unfavorable changes in the fair value of securities of $0.4 billion
•Favorable litigation related items of $0.1 billion
•Loss on divestiture of $0.2 billion.
•An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
MedTech segment income before tax includes:
•Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
•Income from litigation settlements of $0.1 billion
(6)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
(7)Long-lived assets include property, plant and equipment, net for fiscal years 2025, and 2024 of $23,169 and $20,518, respectively, and intangible assets and goodwill, net for fiscal years 2025 and 2024 of $99,175 and $81,818, respectively.

Historical Timeline

Fiscal YearFiled
2025Feb 11, 2026Showing above
2024Feb 13, 2025
2023Feb 16, 2024
2022Feb 17, 2022
2021Feb 22, 2021
2019Feb 18, 2020
2018Feb 20, 2019
2017Feb 21, 2018
2016Feb 24, 2016

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesDebtStock CompensationNew StandardsPay vs Performance